Voelcker Academy

Research Symposium 2012

 

previous next
 
Samantha Van Koughnet

Purinergic Stimulation Increases Treatment Window Following MCAO

Samantha Van Koughnet

Mentor(s): Lora Watts, PhD, and Timothy Duong, PhD

  • Stroke is the third leading cause of death and long-term disability in the United States.
  • More than 800,000 people die each year from stroke in the United States.
  • A stroke results from the blockage of an artery to the brain due to thrombosis or an embolus, which travels to the brain from another artery or the heart.
  • The most common form of stroke is an ischemic stroke(87%).
  • The only approved drug for treatment is recombinant tissue plasminogen activator (rt-PA), however only 3-8% of all patients are eligible to receive this therapy as is associated with a high risk of hemorrhagic transformation.
  • It is critical to find new or combination therapy options to extend the treatment window for patients suffering from ischemic stroke.
  • We predict that 2meSADP will delay infarct growth following embolic stroke by maintaining energetics and extending tissue survival allowing rt-PA to restore blood flow to the ischemic penumbra.